FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
247 letters match. Newest first.
-
DrugsSovereign Pharmaceuticals, LLC
FDA cited Sovereign Pharmaceuticals for manufacturing failures in bulk tablets, inadequate out-of-specification (OOS) investigations, quality-unit lapses, and an unapproved biological product.
High risk -
DrugsAmerican Cleaning Solutions
FDA warned American Cleaning Solutions after a 2022 inspection found hand sanitizer made with inadequate cleaning, unvalidated processes, and substituted ethanol.
High risk -
DrugsEksa Mills S.A. de C.V.
FDA cited Eksa Mills for CGMP violations, including shared-equipment contamination risks, after an April 2022 inspection of its Mexican drug facility.
High risk -
DrugsSanitizer Supply LLC
FDA warns Sanitizer Supply LLC that its hand sanitizer wipes and sanitizers lacked required potency and microbial testing before release.
High risk -
DrugsEpisciences Inc.
FDA warns Episciences Inc. that its Boise, Idaho plant made OTC drugs without adequate batch testing, process validation and failure investigations.
High risk -
DrugsVerde Cosmetic Labs LLC
FDA warned Verde Cosmetic Labs after an inspection found inadequate CGMP controls for OTC topical drugs, including cleaning and water system failures.
High risk -
BiologicsVitti Labs, LLC
FDA warns Vitti Labs over unapproved umbilical cord and amniotic membrane products and sterile manufacturing failures.
High risk -
DrugsDSP Skin Care LLC
FDA cites DSP Skin Care for manufacturing failures and unapproved, misbranded Hongosan antifungal drugs.
High risk -
DrugsCustom Research Labs Inc.
FDA warned Custom Research Labs Inc. about manufacturing-practice violations and unapproved, misbranded OTC drugs, including hand sanitizers and topical analgesics.
High risk -
DrugsBi-Coastal Pharma International
FDA warned Bi-Coastal Pharma International about adulterated drugs due to poor complaint handling, quality-unit oversight, batch release, and training.
High risk -
DrugsBioiberica, SAU
FDA warned Bioiberica over unvalidated rework and missing stability testing of API batches at its Spain plant.
High risk -
DrugsGenlabs Corporation
FDA warns Genlabs Corporation of Chino, California, that its OTC hand soaps are adulterated and misbranded after finding serious CGMP failures.
High risk -
DrugsMirfeel Korea Co., Ltd.
Mirfeel Korea's hand sanitizer contained benzene and had testing failures; FDA also says food-pouch packaging misbranded.
High risk -
DrugsMonarch PCM, LLC
Monarch PCM, LLC made unapproved skin drugs and broke manufacturing rules, with microbial contamination and weak investigations.
High risk -
BiologicsRe-Gen Active Lab, Inc.
FDA warned Re-Gen Active Lab over unapproved amniotic/umbilical cord injectables and serious sterility failures.
High risk -
DrugsColorful Products Corporation
FDA warned Colorful Products Corporation about serious current good manufacturing practice (CGMP) failures for its over-the-counter topical drugs and hand sanitizers.
High risk -
DrugsThe W.S. Badger Company, Inc.
FDA warned W.S. Badger over repeat manufacturing-quality failures in OTC drug products, including sunscreen process, cleaning, test-method, and OOS investigation problems.
High risk -
DrugsGuangzhou Zhongkebaishi Health Industry Co., Ltd.
Guangzhou Zhongkebaishi's Hand Sanitizer Gel, labeled 75% ethanol, tested at 51% and was refused US import.
High risk -
DrugsUltra Seal Corporation
FDA warns Ultra Seal and ULTRAtab over manufacturing quality failures in over-the-counter drug cleaning, testing, and release.
High risk -
DrugsYusef Manufacturing Laboratories, LLC
FDA warned Yusef Manufacturing Laboratories over serious CGMP violations in its OTC drugs and hand sanitizers, including untested ethanol.
High risk -
DrugsNDAL Mfg Inc.
NDAL Mfg's honey nasal sprays had manufacturing-rule violations, microbial contamination, and lacked FDA approval as new drugs.
High risk -
DrugsAgropharma Laboratories, Inc.
FDA cited Agropharma Laboratories in Salinas, Puerto Rico, for serious manufacturing violations affecting its OTC antiseptics and hand sanitizers.
High risk -
DrugsAccu Bio-Chem Laboratories
FDA warned Accu Bio-Chem Laboratories, a contract OTC drug-testing lab, over inadequate failing-result investigations, method verification, and data controls.
Medium -
DevicesCardioQuip, LLC
CardioQuip sold significantly modified cardiac heater-cooler devices without required FDA clearance and with quality system violations.
High risk -
DrugsIndiana Chem-Port
Indiana Chem-Port API manufacturer cited for CGMP deviations including dirty equipment, unvalidated processes, and cleaning failures.
High risk -
DrugsHealth Plus Inc.
FDA warned Health Plus Inc. over manufacturing quality failures in its Super Colon Cleanse laxative made in Chino, California.
High risk -
DrugsCosmo Bio Co., Ltd.
FDA cited South Korea's Cosmo Bio for CGMP failures and for selling an unapproved, misbranded acne drug serum in the U.S.
High risk -
DrugsHubei Kangzheng Pharmaceutical Co., Ltd.
FDA warns Hubei Kangzheng over non-sterile ophthalmic drops, CGMP failures, and unapproved/misbranded pi yen chin.
High risk -
DrugsSanitor Corporation
Sanitor Corporation was cited for CGMP violations after hand sanitizer failed microbial testing and skin-bleaching drugs were sold without approval.
High risk -
BiologicsSurgenex LLC
FDA warned Surgenex it sold unapproved umbilical cord and amniotic membrane products for injection without a biologics license and with serious manufacturing problems.
High risk -
DrugsMatthew 7:25 Inc dba Thrive Pharmacy
FDA says Thrive Pharmacy compounded drugs without valid prescriptions and released subpotent buprenorphine troches, making them adulterated and misbranded.
High risk -
DrugsMarcus Research Laboratory, Inc.
FDA warned Marcus Research Laboratory after a May 2021 inspection found it released povidone iodine API made after reactor fires and smoke without fully testing for contamination.
High risk -
DrugsLaboratorio Pharma International SRL
FDA warns Laboratorio Pharma International over CGMP failures, unapproved GELAZUL, misbranding, and incomplete beta-lactam separation.
High risk -
DrugsFurley Bioextracts SDN BHD
FDA warns Furley Bioextracts over manufacturing failures and unapproved PainFix Relief Gel for the U.S. market.
High risk -
DrugsGulsah Uretim Kozmetik Sanayi Anonim Sirketi
Turkish OTC drug maker Gulsah failed to test its products and ingredients, and FDA blocked its U.S. imports.
High risk -
DrugsNatural Beauty Care Pty Ltd
FDA warned Natural Beauty Care Pty Ltd that its OTC drugs are adulterated due to CGMP failures and no finished-product or ingredient testing.
High risk -
BiologicsUtah Cord Bank LLC dba Utah Cell Bank
Utah Cell Bank made unapproved injectable stem cell products and fell short on sterility and manufacturing controls, FDA found.
High risk -
DrugsMaitland Labs of Central Florida
FDA warns Maitland Labs of Central Florida over sterile compounded drugs with manufacturing quality failures, mislabeling, and unapproved new drug violations.
High risk -
DrugsBBC Group Limited
FDA cites BBC Group Limited for data integrity, lab, equipment failures and unapproved, misbranded hand sanitizers.
High risk -
DrugsSanit Technologies, LLC dba Durisan
FDA says Sanit Technologies (Durisan) released contaminated alcohol-free hand sanitizer, including Burkholderia cepacia, made with contaminated water.
High risk -
DrugsSyntec Pharma Corp
FDA warned Syntec Pharma Corp, an API repackager in Farmingdale, New York, that weak cross-contamination controls and quality oversight made its drugs adulterated.
High risk -
DrugsBiotek India
Biotek India, an OTC drug maker, lacked active-ingredient testing and sold an unapproved 99% isopropyl rubbing alcohol.
High risk -
DrugsBioLyte Laboratories, LLC
FDA cited BioLyte Laboratories for manufacturing failures and unapproved silver, CBD, and magnesium drug products.
High risk -
DrugsDibar Nutricional S. de R.L. de C.V.
Dibar Nutricional's OTC drugs drew FDA CGMP violations and an import alert over missing testing.
High risk -
DrugsFoshan Biours Biosciences Co., Ltd.
Foshan Biours Biosciences, an OTC patch maker, lacked release testing, cleaning validation, and stability data, so FDA says its drugs are adulterated.
High risk -
DrugsAllay Pharmaceuticals, LLC
FDA warned Allay Pharmaceuticals over CGMP failures and sub-potent tablets, and distribution of an unapproved biological product.
High risk -
DrugsYuyao YiJia Daily Chemical Co., Ltd.
Yuyao YiJia, a Chinese OTC drug and hand sanitizer maker, lacked finished-product, component and stability testing and an adequate quality unit.
High risk